Literature DB >> 11176222

The ischaemic penumbra.

O Touzani1, S Roussel, E T MacKenzie.   

Abstract

The concept of an ischaemic penumbra, surrounding a focal cerebral lesion, is now widely accepted, although no universal definition of the 'penumbra' exists. In the present review, we consider the penumbra as that volume of brain tissue at the periphery of a focal, irreversibly damaged area that is threatened by recruitment into necrosis. Implicit to such a definition are several secondary concepts. First, the penumbra is both spatial, in that it surrounds the densely ischaemic core, but it is also temporal, in that its evolution toward infarction is a relatively progressive phenomenon. The pertinent literature is summarized. Second, penumbral tissue is potentially salvageable; the most recent animal studies are reviewed. Third, because electrically silent and pathologically damaged tissues have identical functional characteristics, it is evident that most clinical rating scales, be they neurological, behavioural, or psychological, are poorly adapted to address the problem of the penumbra. Finally, the penumbral tissue is remarkably and intensively 'active': multiple processes of cell death and repair occur and involve molecular mechanisms, electrophysiology and the vasculature.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176222     DOI: 10.1097/00019052-200102000-00013

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  9 in total

1.  A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro.

Authors:  Anna Maria Pugliese; Elisabetta Coppi; Giampiero Spalluto; Renato Corradetti; Felicita Pedata
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  Magnetic resonance diffusion-perfusion mismatch in acute ischemic stroke: An update.

Authors:  Feng Chen; Yi-Cheng Ni
Journal:  World J Radiol       Date:  2012-03-28

3.  Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat.

Authors:  Nicholas J Mulcahy; Jerard Ross; Nancy J Rothwell; Sarah A Loddick
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 4.  The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain?

Authors:  Herve Boutin; Ian Kimber; Nancy J Rothwell; Emmanuel Pinteaux
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

5.  A critical role of neural-specific JNK3 for ischemic apoptosis.

Authors:  Chia-Yi Kuan; Alan J Whitmarsh; Derek D Yang; Guanghong Liao; Aryn J Schloemer; Chen Dong; Jue Bao; Kenneth J Banasiak; Gabriel G Haddad; Richard A Flavell; Roger J Davis; Pasko Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

6.  Prion protein accumulation and neuroprotection in hypoxic brain damage.

Authors:  Neil F McLennan; Paul M Brennan; Alisdair McNeill; Ioan Davies; Andrew Fotheringham; Kathleen A Rennison; Diane Ritchie; Francis Brannan; Mark W Head; James W Ironside; Alun Williams; Jeanne E Bell
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

7.  Interventional neuroradiology of stroke, still not dead.

Authors:  Vitor Mendes Pereira; Karl-Olof Lövblad
Journal:  World J Radiol       Date:  2013-12-28

8.  Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway.

Authors:  Lauren J Simmons; Monique C Surles-Zeigler; Yonggang Li; Gregory D Ford; Gale D Newman; Byron D Ford
Journal:  J Neuroinflammation       Date:  2016-09-06       Impact factor: 8.322

9.  Transcriptomic analysis of neuregulin-1 regulated genes following ischemic stroke by computational identification of promoter binding sites: A role for the ETS-1 transcription factor.

Authors:  Monique C Surles-Zeigler; Yonggang Li; Timothy J Distel; Hakeem Omotayo; Shaokui Ge; Byron D Ford
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.